Human breast tumours are diverse in their natural history and in their responsiveness to treatments. Variation in transcriptional programs accounts for much of the biological diversity of human cells and tumours. In each cell, signal transduction and regulatory systems transduce information from the cell’s identity to its environmental status, thereby controlling the level of expression of every gene in the genome. Here we have characterized variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals, using complementary DNA microarrays representing 8,102 human genes.
These patterns provided a distinctive molecular portrait of each tumour. Twenty of the tumours were sampled twice, before and after a 16-week course of doxorubicin chemotherapy, and two tumours were paired with a lymph node metastasis from the same patient. Gene expression patterns in two tumour samples from the same individual were almost always more similar to each other than either was to any other sample.
Sets of co-expressed genes were identified for which variation in messenger RNA levels could be related to specific features of physiological variation. The tumours could be classified into subtypes distinguished by pervasive differences in their gene expression patterns.
Description: BP-554 maleate is a selective agonist of 5-HT1A receptor [1]. The 5-HT1A receptor is a G protein-coupled receptor for endogenous neurotransmitter serotonin (5-HT) and mediates inhibitory neurotransmission. BP-554 maleate is a selective 5-HT1A receptor agonist.
Description: BP-554 maleate is a selective agonist of 5-HT1A receptor [1]. The 5-HT1A receptor is a G protein-coupled receptor for endogenous neurotransmitter serotonin (5-HT) and mediates inhibitory neurotransmission. BP-554 maleate is a selective 5-HT1A receptor agonist.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A polyclonal antibody for detection of AI-BP from Human, Mouse, Rat. This AI-BP antibody is for WB , IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human AI-BP at AA range: 90-170
Description: A polyclonal antibody for detection of AI-BP from Human, Mouse, Rat. This AI-BP antibody is for WB , IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human AI-BP at AA range: 90-170
Description: A polyclonal antibody for detection of AI-BP from Human, Mouse, Rat. This AI-BP antibody is for WB , IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human AI-BP at AA range: 90-170
Description: Interleukin-18-binding protein (IL18BP) is also known as Tadekinig-alfa, IL18BPa, which functions as an IL18 inhibitor. IL18BP is a secreted protein which contains one Ig-like C2-type (immunoglobulin-like) domain. IL18BP does not have a transmembrane domain and hence is not anchored to the cell membrane. IL18BP is strongly expressed in heart, lung, placenta and spleen. Isoform A of IL18BP binds to IL-18 and inhibits its activity. IL18BP also functions as an inhibitor of the early TH1 cytokine response. IL18BP suppresses the production of IFN-gamma resulting in reduced T-helper type 1 immune responses.
Description: Interleukin-18-binding protein (IL18BP) is also known as Tadekinig-alfa, IL18BPa, which functions as an IL18 inhibitor. IL18BP is a secreted protein which contains one Ig-like C2-type (immunoglobulin-like) domain. IL18BP does not have a transmembrane domain and hence is not anchored to the cell membrane. IL18BP is strongly expressed in heart, lung, placenta and spleen. Isoform A of IL18BP binds to IL-18 and inhibits its activity. IL18BP also functions as an inhibitor of the early TH1 cytokine response. IL18BP suppresses the production of IFN-gamma resulting in reduced T-helper type 1 immune responses.
Description: A polyclonal antibody for detection of Ran BP-6 from Human, Mouse, Rat, Monkey. This Ran BP-6 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Ran BP-6 at AA range: 770-850
Description: A polyclonal antibody for detection of Ran BP-6 from Human, Mouse, Rat, Monkey. This Ran BP-6 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Ran BP-6 at AA range: 770-850
Description: A polyclonal antibody for detection of Ran BP-6 from Human, Mouse, Rat, Monkey. This Ran BP-6 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Ran BP-6 at AA range: 770-850
Description: A polyclonal antibody for detection of Ran BP-17 from Human, Mouse. This Ran BP-17 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human Ran BP-17 at AA range: 120-200
Description: A polyclonal antibody for detection of Ran BP-17 from Human, Mouse. This Ran BP-17 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human Ran BP-17 at AA range: 120-200
Description: A polyclonal antibody for detection of Ran BP-17 from Human, Mouse. This Ran BP-17 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human Ran BP-17 at AA range: 120-200
Description: A polyclonal antibody for detection of Lck BP-1 from Human. This Lck BP-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Lck BP-1 around the non-phosphorylation site of Y397
×
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Human cancer cells typically harbour multiple chromosomal aberrations, nucleotide substitutions and epigenetic modifications that drive malignant transformation. The Cancer Genome Atlas (TCGA) pilot project aims to assess the value of large-scale multi-dimensional analysis of these molecular characteristics in human cancer and to provide the data rapidly to the research community.
Here we report the interim integrative analysis of DNA copy number, gene expression and DNA methylation aberrations in 206 glioblastomas–the most common type of adult brain cancer–and nucleotide sequence aberrations in 91 of the 206 glioblastomas.
This analysis provides new insights into the roles of ERBB2, NF1 and TP53, uncovers frequent mutations of the phosphatidylinositol-3-OH kinase regulatory subunit gene PIK3R1, and provides a network view of the pathways altered in the development of glioblastoma.
Furthermore, integration of mutation, DNA methylation and clinical treatment data reveals a link between MGMT promoter methylation and a hypermutator phenotype consequent to mismatch repair deficiency in treated glioblastomas, an observation with potential clinical implications.
Together, these findings establish the feasibility and power of TCGA, demonstrating that it can rapidly expand knowledge of the molecular basis of cancer.
The sequence of the human genome.
A 2.91-billion base pair (bp) consensus sequence of the euchromatic portion of the human genome was generated by the whole-genome shotgun sequencing method.
The 14.8-billion bp DNA sequence was generated over 9 months from 27,271,853 high-quality sequence reads (5.11-fold coverage of the genome) from both ends of plasmid clones made from the DNA of five individuals.
Two assembly strategies-a whole-genome assembly and a regional chromosome assembly-were used, each combining sequence data from Celera and the publicly funded genome effort.
The public data were shredded into 550-bp segments to create a 2.9-fold coverage of those genome regions that had been sequenced, without including biases inherent in the cloning and assembly procedure used by the publicly funded group.
This brought the effective coverage in the assemblies to eightfold, reducing the number and size of gaps in the final assembly over what would be obtained with 5.11-fold coverage.
The two assembly strategies yielded very similar results that largely agree with independent mapping data. The assemblies effectively cover the euchromatic regions of the human chromosomes.
More than 90% of the genome is in scaffold assemblies of 100,000 bp or more, and 25% of the genome is in scaffolds of 10 million bp or larger. Analysis of the genome sequence revealed 26,588 protein-encoding transcripts for which there was strong corroborating evidence and an additional approximately 12,000 computationally derived genes with mouse matches or other weak supporting evidence.
Although gene-dense clusters are obvious, almost half the genes are dispersed in low G+C sequence separated by large tracts of apparently noncoding sequence.
Only 1.1% of the genome is spanned by exons, whereas 24% is in introns, with 75% of the genome being intergenic DNA. Duplications of segmental blocks, ranging in size up to chromosomal lengths, are abundant throughout the genome and reveal a complex evolutionary history.
Comparative genomic analysis indicates vertebrate expansions of genes associated with neuronal function, with tissue-specific developmental regulation, and with the hemostasis and immune systems.
DNA sequence comparisons between the consensus sequence and publicly funded genome data provided locations of 2.1 million single-nucleotide polymorphisms (SNPs). A random pair of human haploid genomes differed at a rate of 1 bp per 1250 on average, but there was marked heterogeneity in the level of polymorphism across the genome.
Less than 1% of all SNPs resulted in variation in proteins, but the task of determining which SNPs have functional consequences remains an open challenge.
Cynthia
